FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048014367> ?p ?o ?g. }

• W3048014367 endingPage "398" @default.
• W3048014367 startingPage "398.1" @default.
• W3048014367 abstract "Background: Vasculopathy is a hallmark of systemic sclerosis (SSc). Laser speckle contrast analysis (LASCA) is a research tool to assess peripheral blood perfusion (PBP) (1). At this moment, its reliability has been attested in SSc patients, but its predictive value for future ischemic digital trophic lesions (DTL) is unknown (1). Objectives: To investigate in an unselected, prospective SSc cohort if baseline LASCA PBP measurements can discriminate between patients who will develop ischemic DTL (iDTL) and those who will not. Methods: Patients (fulfilling 2013 ACR/EULAR criteria and/or 2001 LeRoy and Medsger criteria) were recruited during the period of December 2017 to September 2018. LASCA was performed at baseline, in standardized conditions (1). Regions of interest (ROIs) (diameter 1 cm) were outlined at the 2 nd -5 th fingertip both volar and dorsal. The ‘average PBP’ of these ROIs was calculated (expressed in arbitrary perfusion units [PU]). A monthly telephone survey was conducted for 1 year to investigate DTL occurrence. DTL were considered ‘ischemic’ if not related to calcinosis. Logistic regression and ROC analysis were used to assess if average PBP is predictive of future iDTL. Results: Of the 106 patients with complete follow-up (92 women [86,8%]; 18 limited SSc [17,0%], 82 limited cutaneous SSc [77,4%], 6 diffuse cutaneous SSc [5,7%]), 29 patients (27,4%) had a DTL history. Forty-nine patients (46,2%) were on vasodilator therapy. Only 7 patients developed at least 1 iDTL during follow-up (6,6%) (Figure 1a). Performing univariate logistic regression (ULR), average PBP was not predictive for future iDTL (Table 1). Of note, analyzing only the patients not taking vasodilators, average PBP in the ‘iDTL group’ (n = 3) was median 46,8 PU (min. 45,6 - max. 68,8) vs. median 141,4 PU (min. 24,4 - max. 269,5) in the ‘no iDTL group’ (n = 54) (Figure 1b). In this subgroup, all 3 patients who developed iDTL (100%) had an average PBP ≤ 70 PU whereas only 9 of the 54 patients without iDTL development (16,7%) had such PBP values. Table 1. Results of ULR Summary statistics ULR Variable iDTL cases (n = 7 ) Non-iDTL cases (n = 99 ) Parameter OR (95% CI ) p ROC AUC (95% CI ) Average PBP (PU ) mean (+/- SD) 123,0 (74,6) 142,9 (61,9) Average PBP (linear ) 0,995 (0,982-1,007) 0,418 0,597 (0,352-0,843) Conclusion: In this pilot study with an unselected day-to-day SSc population, where patients were allowed to continue vasodilators, there was an unexpected low iDTL incidence, undermining the power of our study. Even though, the observations in the subgroup of patients not taking vasodilators deserve future investigation to assess whether low PBP values, as measured by LASCA, are associated with a higher iDTL incidence. References: [1]Cutolo M, Vanhaecke A, et al. Autoimmun Rev. 2018;17(8):775-80. Figure 1. Distribution of ‘average PBP’ as measured by LASCA for ‘no iDTL group’ and ‘iDTL group’ Disclosure of Interests: Claire Debusschere: None declared, Amber Vanhaecke: None declared, Maurizio Cutolo Grant/research support from: Bristol-Myers Squibb, Actelion, Celgene, Consultant of: Bristol-Myers Squibb, Speakers bureau: Sigma-Alpha, Ellen Deschepper: None declared, Vanessa Smith Grant/research support from: The affiliated company received grants from Research Foundation - Flanders (FWO), Belgian Fund for Scientific Research in Rheumatic diseases (FWRO), Boehringer Ingelheim Pharma GmbH & Co and Janssen-Cilag NV, Consultant of: Boehringer-Ingelheim Pharma GmbH & Co, Speakers bureau: Actelion Pharmaceuticals Ltd, Boehringer-Ingelheim Pharma GmbH & Co and UCB Biopharma Sprl" @default.
• W3048014367 created "2020-08-13" @default.
• W3048014367 creator A5021675382 @default.
• W3048014367 creator A5022038095 @default.
• W3048014367 creator A5022053818 @default.
• W3048014367 creator A5028547482 @default.
• W3048014367 creator A5050377857 @default.
• W3048014367 date "2020-06-01" @default.
• W3048014367 modified "2023-09-25" @default.
• W3048014367 title "THU0334 LASER SPECKLE CONTRAST ANALYSIS FOR MEASUREMENT OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLEROSIS PATIENTS: CAN IT PREDICT FUTURE ISCHEMIC DIGITAL TROPHIC LESIONS?" @default.
• W3048014367 cites W2896676995 @default.
• W3048014367 doi "https://doi.org/10.1136/annrheumdis-2020-eular.2438" @default.
• W3048014367 hasPublicationYear "2020" @default.
• W3048014367 type Work @default.
• W3048014367 sameAs 3048014367 @default.
• W3048014367 citedByCount "0" @default.
• W3048014367 crossrefType "journal-article" @default.
• W3048014367 hasAuthorship W3048014367A5021675382 @default.
• W3048014367 hasAuthorship W3048014367A5022038095 @default.
• W3048014367 hasAuthorship W3048014367A5022053818 @default.
• W3048014367 hasAuthorship W3048014367A5028547482 @default.
• W3048014367 hasAuthorship W3048014367A5050377857 @default.
• W3048014367 hasBestOaLocation W30480143671 @default.
• W3048014367 hasConcept C126322002 @default.
• W3048014367 hasConcept C126838900 @default.
• W3048014367 hasConcept C141071460 @default.
• W3048014367 hasConcept C144301174 @default.
• W3048014367 hasConcept C146957229 @default.
• W3048014367 hasConcept C151956035 @default.
• W3048014367 hasConcept C154945302 @default.
• W3048014367 hasConcept C164705383 @default.
• W3048014367 hasConcept C188816634 @default.
• W3048014367 hasConcept C2776502983 @default.
• W3048014367 hasConcept C38180746 @default.
• W3048014367 hasConcept C41008148 @default.
• W3048014367 hasConcept C71924100 @default.
• W3048014367 hasConceptScore W3048014367C126322002 @default.
• W3048014367 hasConceptScore W3048014367C126838900 @default.
• W3048014367 hasConceptScore W3048014367C141071460 @default.
• W3048014367 hasConceptScore W3048014367C144301174 @default.
• W3048014367 hasConceptScore W3048014367C146957229 @default.
• W3048014367 hasConceptScore W3048014367C151956035 @default.
• W3048014367 hasConceptScore W3048014367C154945302 @default.
• W3048014367 hasConceptScore W3048014367C164705383 @default.
• W3048014367 hasConceptScore W3048014367C188816634 @default.
• W3048014367 hasConceptScore W3048014367C2776502983 @default.
• W3048014367 hasConceptScore W3048014367C38180746 @default.
• W3048014367 hasConceptScore W3048014367C41008148 @default.
• W3048014367 hasConceptScore W3048014367C71924100 @default.
• W3048014367 hasIssue "Suppl 1" @default.
• W3048014367 hasLocation W30480143671 @default.
• W3048014367 hasOpenAccess W3048014367 @default.
• W3048014367 hasPrimaryLocation W30480143671 @default.
• W3048014367 hasRelatedWork W2002120878 @default.
• W3048014367 hasRelatedWork W2003938723 @default.
• W3048014367 hasRelatedWork W2047967234 @default.
• W3048014367 hasRelatedWork W2084133707 @default.
• W3048014367 hasRelatedWork W2118496982 @default.
• W3048014367 hasRelatedWork W2364998975 @default.
• W3048014367 hasRelatedWork W2439875401 @default.
• W3048014367 hasRelatedWork W4238867864 @default.
• W3048014367 hasRelatedWork W2519357708 @default.
• W3048014367 hasRelatedWork W2525756941 @default.
• W3048014367 hasVolume "79" @default.
• W3048014367 isParatext "false" @default.
• W3048014367 isRetracted "false" @default.
• W3048014367 magId "3048014367" @default.
• W3048014367 workType "article" @default.